Sermorelin: Evidence, Legal Status, and Safety

Sermorelin was actually FDA-approved decades ago under the brand Geref, for diagnostic use and pediatric growth-hormone-deficiency treatment. That branded product was discontinued, and sermorelin is now used almost entirely through compounding pharmacies, not as an FDA-approved product on the market today. For its current popular use, anti-aging, recovery, sleep, and body composition in healthy adults, the evidence is Tier C: the old, now-discontinued approval was for a narrow pediatric diagnostic and deficiency indication, not the wellness use it is sold for today, and that older approval should not be read as evidence for the current use. Multiple industry sources describe sermorelin as currently compoundable and available through compounding pharmacies with a prescription, a comparatively more permissive position than the reported Category 2 restriction on CJC-1295 and ipamorelin. That specific legal-status claim has not been independently confirmed against the FDA's current 503A bulk-substance list, so it should be treated as unverified, pending confirmation, rather than settled fact. Andrew Huberman has personally disclosed, on his Huberman Lab podcast, “I've taken Sermorelin on and off for the last couple of years,” and notes it can reduce REM sleep; he also confirms tesamorelin's narrower FDA-approved use in the same episode, for comparison.